Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma

Carcinoma, Bronchogenic

Bronchial Neoplasms

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Antineoplastic Agents

All Drugs and Chemicals

Micronutrients

Hematinics

Vitamins

Carboplatin

Bevacizumab

Pemetrexed

Cisplatin

Atezolizumab

Antibodies

Antibodies, Monoclonal

Immunoglobulins

Antineoplastic Agents, Immunological

Angiogenesis Inhibitors

Growth Inhibitors

Enzyme Inhibitors

Folic Acid

Vitamin B Complex

Folic Acid Antagonists

Immune Checkpoint Inhibitors

Immunologic Factors

Folinic Acid

Folate

Vitamin B9

4 cycles of induction every 3 weeks with :

* Carboplatin area under curve 6 mg/mL per minute per IV route or Cisplatin 75 mg/m² per IV route
* Pemetrexed 500 mg/m² per IV route
* Atezolizumab 1200 mg per IV route
* Bevacizumab 15 mg/kg per IV route For patients without disease progression, treatment will be followed by maintenance therapy by Atezolizumab + Pemetrexed and Bevacizumab administered at the same dosage on 3-week cycles

4 cycles of induction every 3 weeks with :

* Carboplatin area under curve 6 mg/mL per minute per IV route or Cisplatin 75 mg/m² per IV route
* Pemetrexed 500 mg/m² per IV route
* Atezolizumab 1200 mg per IV route For patients without disease progression, treatment will be followed by maintenance therapy by Atezolizumab + Pemetrexed administered at the same dosage on 3-week cycles

4 cycles of induction every 3 weeks of cisplatine,pemetrexed, atezolizumab + bevacizumab and patients without disease progression, treatment will be followed by maintenance therapy by Atezolizumab + Pemetrexed +/- Bevacizumab administered at the same dosage on 3-week cycles

Carboplatin + Pemetrexed + Atezolizumab + Bevacizumab

Carboplatin + Pemetrexed + Atezolizumab

BYLICKI Olivier, MD

GRELLARD Jean-Michel, Project manager

JUSTEAU Gregoire, MD

HOMINAL Stéphane, MD

DESCOURT Renaud, MD

Sebastien COURAUD, PhD

GERVAIS Radj, MD

GRELLARD Jean-Michel

JANICOT Henri, MD

MONNET Isabelle, MD

MORO-SIBILOT Denis, PhD

Acya BIZIEUX, MD

Diane MOREAU, MD

Eric HUCHOT, MD

Alexis CORTOT, MD

VERGNENEGRE Alain, PhD

PEROL Maurice, MD

GREILLER Laurent, PhD

Hugues MOREL, MD

DOUBRE Helene, MD

DANIEL Catherine, MD

VEILLON Rémi, MD

COURAUD Sébastien, MD

LENA Hervé, MD

BOTA Suzanna, MD

FOURNEL Pierre, PhD

SCHOTT Roland, MD

PALEIRON Nicolas, MD

BIGAY GAME Laurence, MD

Gonzague DE CHABOT, MD

ARPIN Dominique, MD

PELONI Jean-Michel, MD

The objective of this study is to assess the efficacy of the combination of Platinum (carboplatin or cisplatin), Pemetrexed, Atezolizumab+/- Bevacizumab if eligible, in stage IIIB/IV non-squamous non-small cell lung cancer patients with progression-enhancing mutations following targeted therapies.

In patients with an EGFR mutation, several phase III studies comparing EGFR tyrosine kinase inhibitors (TKIs) with chemotherapy have shown a benefit of TKI over chemotherapy, with no demonstrated benefit on overall survival. After a first line of treatment with a TKI, most patients progress and are eligible according to the mechanism of progression to a TKI of 3rd generation in case of T790M resistance or chemotherapy. In patients with ALK translocation, crizotinib has been shown to be beneficial in first line compared to a platinum doublet.Despite these major advances, most patients are progressing after targeted treatments and chemotherapy and are facing the problem of anti-PD1 / PDL1 treatment.

Open-label, multicentre, non-randomized two parallel cohorts phase II study

A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies

A Multicentre Phase II, Open-label, Non-randomized Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/- Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies

GFPC

Centre Francois Baclesse

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies	NCT04042558	NSCLC Stage III... NSCLC Stage IV EGFR Gene Mutat... ALK Gene Rearra... ROS1 Gene Mutat...	Carboplatin + P... Carboplatin + P...	18 Years - 75 Years	Centre Francois Baclesse
A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies	NCT04042558	NSCLC Stage III... NSCLC Stage IV EGFR Gene Mutat... ALK Gene Rearra... ROS1 Gene Mutat...	Carboplatin + P... Carboplatin + P...	18 Years - 75 Years	Centre Francois Baclesse

Spots Global Cancer Trial Database for carboplatin + pemetrexed + atezolizumab + bevacizumab